Teva Pharmaceutical Industries Limited (BUL:TEVA)
Bulgaria · Delayed Price · Currency is BGN · Price in EUR | Market Cap | 76.70B +99.5% |
| Revenue (ttm) | 28.83B +4.1% |
| Net Income | 1.18B |
| EPS | 1.00 |
| Shares Out | n/a |
| PE Ratio | 65.25 |
| Forward PE | 13.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 34.60 |
| Day's Range | n/a |
| 52-Week Range | 34.60 - 35.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About BUL:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva announces published review on dopamine pathways in Tourette syndrome
Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced that the Journal of Child Neurology published a comprehensive review examining dopamine pathways in Tourette ...
Teva announces new data for ecopipam
Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new data for ecopipam. Presented at the International Congress of Parkinson’s Disease and Movement Disorders ...
Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neuro...
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-...
Teva, Samsung Bioepis expand strategic partnership to advance biosimilars
Samsung Bioepis and Teva (TEVA) Pharmaceutical Industries announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimil...
Teva initiated with a Buy at TD Cowen
TD Cowen analyst Joseph Thome initiated coverage of Teva (TEVA) with a Buy rating and $55 price target Teva is a global biopharma company that leverages both a base of…
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)-- #Fasenra--Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered i...
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer.
Teva announces FDA approval of Degevma as a biosimilar to Xgeva
Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention of bone complications in adults with advanced cancer...
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) ha...
Teva Releases Q3 2026 Aide Memoire
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “I...
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quar...
Teva initiated with an Outperform at Oppenheimer
Oppenheimer analyst Les Sulewski initiated coverage of Teva (TEVA) with an Outperform rating and $50 price target The company is entering the acceleration phase of its transformation, the analyst tell...
Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
MONTPELLIER, France--(BUSINESS WIRE)--Medincell's partner Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY®, two treatments utilizing Medincell's proprietar...
Teva presents new new real-world data on uzedy at Psych Congress
Teva (TEVA) Pharmaceuticals announced new real-world data evaluating treatment continuity, healthcare resource utilization and clinical outcomes among adults with schizophrenia and bipolar I disorder ...
Teva announces new olanzapine post-hoc data
Teva (TEVA) Pharmaceuticals “announced the presentation of new olanzapine LAI post hoc data from the pivotal SOLARIS Phase 3 trial as well as analyses supporting treatment switch strategies. The SOLAR...
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choic...
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating...
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanza...
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept.
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 b...
Leerink starts Teva with an Outperform with new strategy ‘clearly bearing fruit’
Leerink initiated coverage of Teva (TEVA) with an Outperform rating and $45 price target Teva’s “Pivot to Growth” strategy is “clearly bearing fruit,” evidenced by strong commercial execution and a…
Teva initiated with an Outperform at Leerink
Leerink initiated coverage of Teva (TEVA) with an Outperform rating and $45 price target
Teva Announces Launch of Offering of Senior Notes
TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose ...
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline